Pharmacy directors are using the growing number of publicly visible drug prices as leverage, new research shows. Manufacturers need to be ready, before those prices become a negotiation tool.
Robert Rouse
Advertisement
Robert Rouse is head of value and access and partner at Beghou.
Articles by Robert Rouse
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
What National Licensure Means for Wholesalers and 3PLs
2
MFN Program Grows to 26 Drugmakers as Nine More Commit to $19.6B in US Manufacturing
3
Beyond the Patent Cliff: Why Generics and Biosimilars Demand Different Playbooks
4
The Difference Between Meeting DSCSA and Mastering It
5